2022
Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease
Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. Journal Of Clinical Oncology 2022, 40: 1174-1185. PMID: 35007144, PMCID: PMC8987226, DOI: 10.1200/jco.21.01755.Peer-Reviewed Original ResearchMeSH KeywordsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteRecurrenceTransplantation ConditioningUnrelated DonorsConceptsChronic GVHDAcute GVHDHost diseaseNonrelapse mortalityT cellsPeripheral blood stem cell graftsBlood stem cell graftsGrade II acute GVHDGrade III acute GVHDNaive T-cell depletionAllogeneic hematopoietic cell transplantationPhase II clinical trialChronic Graft-VersusUnrelated donor graftsT-cell depletionHematopoietic cell transplantationTotal body irradiationMemory T cellsRelapse-free survivalStem cell graftsNaive T cellsApparent excess riskCell transplantation approachesGastrointestinal GVHDGraft-Versus
2017
Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma
Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationT-cell lymphomaAllogeneic hematopoietic stem cell transplantationNovel agentsPeripheral T-cell lymphomaPositive T-cell lymphomaDiagnosis of CD8Retrospective case seriesStandardized treatment strategyStem cell transplantationPotential curative therapyCourse of treatmentPromising treatment modalityHistone deacetylase inhibitorsSustained remissionCombination chemotherapyCurative therapyCase seriesPoor outcomeRare subtypeTreatment courseAvailable therapiesCell transplantationTreatment modalitiesTreatment strategies
2016
Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration
Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.Peer-Reviewed Original ResearchAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugDrug Administration ScheduleEtoposideFemaleHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousMaleMelphalanMiddle AgedTransplantation ConditioningTransplantation, AutologousYoung Adult
2015
Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts
Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts. Journal Of Clinical Investigation 2015, 125: 2677-2689. PMID: 26053664, PMCID: PMC4563691, DOI: 10.1172/jci81229.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdrenal Cortex HormonesAdultAnimalsChronic DiseaseDisease-Free SurvivalFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHumansKaplan-Meier EstimateLeukemiaLymphocyte DepletionMaleMiceMiddle AgedMyelodysplastic SyndromesTissue DonorsT-Lymphocyte SubsetsTransplantation ConditioningTransplantation, HomologousYoung AdultConceptsHematopoietic stem cell transplantationStem cell graftsChronic GVHDT cellsCell graftsT-cell-depleted stem cell graftsPeripheral blood stem cell graftsAllogeneic hematopoietic stem cell transplantationBlood stem cell graftsFunctional T-cell memoryT-cell-replete graftsPathogen-specific T cellsSingle-arm clinical trialT-cell recoveryVirus-specific immunityStem cell allograftsTotal body irradiationMemory T cellsStem cell transplantationT cell memoryAcute leukemia patientsHigh-risk leukemiaNaive T cellsAcute GVHDSevere GVHD
2012
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant
Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplantation 2012, 48: 646-650. PMID: 23165491, DOI: 10.1038/bmt.2012.218.Peer-Reviewed Original ResearchConceptsAllogeneic PBSC transplantCutaneous toxicityConditioning regimenPBSC transplantsToxic erythemaLow treatment-related mortalityDoses of BUEffective conditioning regimenPalms/solesTreatment-related mortalityEvaluable patientsMost patientsMedian onsetStandard dosesTransplant physiciansClinical presentationScrotal involvementSpecific therapyAllergic reactionsInappropriate treatmentRetrospective analysisHigh incidencePatientsMyeloid neoplasiaBU/
2000
Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
Marshall N, Howe J, Formica R, Krause D, Wagner J, Berliner N, Crouch J, Pilip I, Cooper D, Blazar B, Seropian S, Pamer E. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000, 96: 2814-21. PMID: 11023516, DOI: 10.1182/blood.v96.8.2814.h8002814_2814_2821.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigen PresentationAntigens, ViralBeta 2-MicroglobulinBiopolymersCD8-Positive T-LymphocytesChildEpstein-Barr Virus InfectionsFeasibility StudiesFemaleGraft SurvivalHematologic NeoplasmsHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanHistocompatibility TestingHLA-A2 AntigenHLA-B7 AntigenHLA-B8 AntigenHumansKidney TransplantationLymphoproliferative DisordersMacromolecular SubstancesMaleMiddle AgedTissue DonorsT-Lymphocyte SubsetsTransplantation ConditioningTransplantation, HomologousViral LoadConceptsEBV-specific T cellsStem cell transplantationT cellsAllo-PBSCTEBV peptidesCell transplantationT lymphocytesAllogeneic peripheral blood stem cell transplantationEpstein-Barr virus–specific T lymphocytesHuman leukocyte antigen (HLA) class I tetramersEBV-specific CD8 T cellsPeripheral blood stem cell transplantationSpecific CD8 T lymphocytesUnrelated cord blood transplantationVirus-specific T lymphocytesBlood stem cell transplantationAllogeneic stem cell transplantationCD8 T cell repertoireAllo-PBSCT patientsEBV genome copiesEpstein-Barr viremiaCD8 T lymphocytesClass I tetramersCord blood transplantationPathogen-specific immunity